Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

Inclusion Criteria

• Males and females ≥18 years old
• Clinical diagnosis of stable, clinically typical actinic keratosis
• A define treatment area on the face or scalp
• Females must be postmenopausal, surgically sterile or otherwise incapable of pregnancy for at least 1 year; or must be using highly effective contraception for at least 90 days prior to treatment with KX2-391 Ointment
• Males who have not had a vasectomy must agree to use barrier contraception
• Participants who in the judgment of the Investigator, are in good general health
• Willing to avoid excessive sun exposure
• Able to comprehend and are willing to sign an informed consent form (ICF)

Exclusion Criteria

• Clinically atypical and/or rapidly changing AK lesions on the treatment area
• Malignancy within 5 years prior to Screening except basal or squamous cell carcinoma not on the treatment area that were treated with curative intent and are without recurrence
• Used any of retinoids at the most 90 days before Visit 1 glucocorticosteroids and methotrexate or other anti-metabolites within, at the most 28 days, before Visit 1
• Used any topical therapies, treatments, or surgical or destructive modalities on the treatment area within, at the most 90 days, before Visit 1
• Currently, or has experienced cutaneous malignancy, sunburn or body art on the treatment area within, at the most 180 days, before Visit 1
• A history of sensitivity and/or allergy to any of the ingredients in the study medication
• A skin disease or condition that, in the opinion of the Investigator, might interfere with the study conduct or evaluations, or which exposes the participant to an unacceptable risk by study participation
• Other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the Investigator, would expose the participant to unacceptable risk by study participation
• Females who are pregnant or nursing
• Participated in an investigational drug trial during which an investigational study medication was administered within 14 days or 5 half-lives of the investigational product, whichever is longer, before dosing.